Lifeboat Foundation

We discuss the state of the art and innovative micro- and nanoscale technologies that are finding niches and opening up new opportunities in medicine, particularly in diagnostic and therapeutic applications. We take the design of point-of-care applications and the capture of circulating tumor cells as illustrative examples of the integration of micro- and nanotechnologies into solutions of diagnostic challenges. We describe several novel nanotechnologies that enable imaging cellular structures and molecular events. In therapeutics, we describe the utilization of micro- and nanotechnologies in applications including drug delivery, tissue engineering, and pharmaceutical development/testing. In addition, we discuss relevant challenges that micro- and nanotechnologies face in achieving cost-effective and widespread clinical implementation as well as forecasted applications of micro- and nanotechnologies in medicine.

Antibody found to block infection by the novel coronavirus SARS-CoV-2 in cells.

The ‘47D11’ antibody targets the ‘spike protein’ of the destructive coronavirus.

Continue reading “Antibody prevents the COVID-19 virus from infecting human cells” »

Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management. In the short time since SARS-CoV2 emerged, much has been learned about the immunopathology of the infection. Here, Xuetao Cao discusses what these early insights imply for drug discovery and clinical management.

A microbe found in mosquitoes that appears to block malaria could be used to control spread of the disease in humans, according to researchers in Kenya and Britain.

In findings published Monday by the journal Nature Communications, the authors describes finding the microbe, Microsporidia MB, in mosquitoes around Lake Victoria in Africa — and that they could not find a single mosquito with the microbe that also had the malaria parasite.

A possible malaria control approach involves the dissemination in mosquitoes of inherited symbiotic microbes to block Plasmodium transmission. However, in the Anopheles gambiae complex, the primary African vectors of malaria, there are limited reports of inherited symbionts that impair transmission. We show that a vertically transmitted microsporidian symbiont (Microsporidia MB) in the An. gambiae complex can impair Plasmodium transmission. Microsporidia MB is present at moderate prevalence in geographically dispersed populations of An. arabiensis in Kenya, localized to the mosquito midgut and ovaries, and is not associated with significant reductions in adult host fecundity or survival. Field-collected Microsporidia MB infected An. arabiensis tested negative for P. falciparum gametocytes and, on experimental infection with P. falciparum, sporozoites aren’t detected in Microsporidia MB infected mosquitoes. As a microbe that impairs Plasmodium transmission that is non-virulent and vertically transmitted, Microsporidia MB could be investigated as a strategy to limit malaria transmission.

The drone-maker won the international award for its autonomous drones which have permitted companies to operate efficiently and flexibly despite the absence of workers around the world. The award was given to Percepto by the US-based company Frost and Sullivan, a business consulting firm involved in market research and analysis, for its ‘technological leadership’ in developing unique docking stations that operate independently without the need for a human operator in close proximity.

UV light kills viruses in air-borne droplets and of the three types of ultraviolet light – UV-A, UV-B and UV-C – UV-C is the most damaging.

UV-C can damage the nucleic acids within an organism and prevent it from replicating. Its use as a disinfectant is fairly common in hospital and laboratory settings.

In Israel, IAI engineers have been working on a system that can work autonomously and automatically in a plane, once given a plan of the aircraft or any other large space.

HOUSTON, May 1, 2020 — Rice University researchers plan to reconfigure their wastewater-treatment technology to capture and deactivate the virus that causes COVID-19. Their chemical-free nanotechnology, introduced earlier this year as a way to kill bacterial “superbugs” and degrade their antibiotic resistance genes in wastewater, will use graphitic carbon nitride to selectively adsorb viruses and then disable them by activating nearby catalysts with light. The team believes that this photocatalytic approach to disinfection — what it calls the “trap-and-zap” treatment approach — could be used to recognize coronaviruses that cause not only COVID-19 but also MERS and SARS.

An injectable antibiotic developed by a team at The Hebrew University of Jerusalem could have a deep impact not only on treating COVID-19 patients, but also on all those affected by antibiotic-resistant infections.

Prof. Yechezkel Barenholz and Dr. Ahuva Cern with their team at the Laboratory of Membrane and Liposome Research at Hadassah-University Medical Center in Jerusalem have been working on improving the performance of drugs in treating different illnesses, including cancer and infectious diseases, for many years. Their method is based on encapsulating the drugs in particles that can be injected into the body.

“We take well-known and established drugs and encapsulate them in two types of particles, called ‘liposomes’ because they are made of lipids, meaning fats,” Barenholz told The Jerusalem Post. “These particles imitate the human cell because they feature a membrane separating the outer world and the inner world of the unit.”

Continue reading “Israeli team finds way to inject drug against COVID-19-related infections” »

The debate is focused on a subset of gain-of-function studies that manipulate deadly viruses to increase their transmissibility or virulence. “This is what happens to viruses in the wild”, explains Carrie Wolinetz, head of the NIH Office of Science Policy. “Gain-of-function experiments allow us to understand how pandemic viruses evolve, so that we can make predictions, develop countermeasures, and do disease surveillance”. Although none of the widely publicised mishaps of 2014 involved such work, the NIH decided to suspend funding for gain-of-function studies involving influenza, MERS-CoV, and SARS-CoV.

The US moratorium on gain-of-function experiments has been rescinded, but scientists are split over the benefits—and risks—of such studies. Talha Burki reports.

On Dec 19, 2017, the US National Institutes of Health (NIH) announced that they would resume funding gain-of-function experiments involving influenza, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus. A moratorium had been in place since October, 2014. At the time, the NIH had stated that the moratorium “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy”. This process has now concluded. It was spearheaded by the National Science Advisory Board for Biosecurity (NSABB) and led to the development of a new framework for assessing funding decisions for research involving pathogens with enhanced pandemic potential. The release of the framework by the Department of Health and Human Services (HHS), of which NIH is part, signalled the end of the funding pause.

Continue reading “Ban on gain-of-function studies ends” »